Abstract Differential prognostic roles of Androgen Receptor (AR) have been proposed in breast cancer (BC) depending on tumour oestrogen receptor (ER) status. This study aimed to evaluate the prognostic and/or predictive significance of AR expression in invasive BC. In this study AR expression was studied on a large (n = 1141) consecutive series of early-stage (I-III) BC using tissue microarray and immunohistochemistry (IHC). AR mRNA expression was assessed in a subset of cases. The prognostic impact of AR mRNA expression was externally validated using the online BC gene expression data sets (n = 25 data sets, 4078 patients). Nuclear AR IHC expression was significantly associated with features of good prognosis including older age, smaller tumour size, lower grade and lobular histology particularly in the ERpositive tumours. AR was associated with ER-related markers GATA3, FOXa1, RERG and BEX1. Negative association was observed with HER2, p53, Ki67, TK1, CD71 and AGTR1. AR Overexpression was associated with longer survival (p \ 0.001), independent of tumour size, grade, stage [p = 0.033, hazard ratio (HR) = 0.80 95 % CI = 0.64-0.98]. Similar associations were maintained in ER? tumours in univariate and multivariate analysis (p \ 0.01) both in patients with and without adjuvant endocrine or chemotherapy. AR mRNA expression showed significant association with tumour grade, molecular subtypes, and longer 10 and 15 years survival in luminal BC. In the external validation cohorts, AR gene expression data were associated with improved patients' outcome (p \ 0.001, HR = 0.84, 95 % CI 0.79-0.90). AR is not only an independent prognostic factor in ER-positive luminal BC but is also expressed in ER-negative tumours. AR could act as a molecular target in patients with ERpositive disease predicting response to adjuvant therapy.
Introduction
Androgen receptor (AR), similar to oestrogen receptor (ER) and progesterone receptor (PR), belongs to the steroid nuclear receptor family (nuclear receptor 3, group C, member 4; NR3C4) [1, 2] . AR is activated when bound by its specific ligands which results in conformational receptor changes and then receptor translocation into the nucleus where it undergoes dimerisation. The dimer binds to its specific hormone receptor elements (HREs) [3] . The AR functions mainly as a DNA-binding transcription factor that regulates gene expression [4] . In-vitro cell line studies revealed that AR potently inhibits ER transactivation and proliferation and promotes apoptosis [5, 6] . However the interaction between AR and ER remains unclear. It has been suggested that signalling through AR replaces oestrogen-dependent signalling and exerts a stimulatory effect through the androgen responsive element, thereby stimulating transcription of steroid responsive genes [7] . In breast cancer (BC), AR is expressed in 50-88 % of cases [8] [9] [10] [11] [12] [13] [14] with an average of 61 % in all BCs and 75 % in ER-positive tumours [15] . Previous studies have shown that AR expression has the potential to predict disease progression [15, 16] , as well as the likelihood and duration of response to therapy when used with medroxyprogesterone acetate [17] . It was shown that reduced AR expression can predict a four-fold increase in the risk of BC-related death in ER-positive BC patients [5] . Studies of ER-negative and triple-negative (TN) BC report conflicting results regarding the prognostic significance of AR with some authors indicating a good prognostic value [18] while others reported it is associated with worse outcome [14] . Molecular classification of BC has also reported the identification of a molecular apocrine class that is characterised by loss of ER expression but with expression of AR and activation of androgen signalling. In a meta-analysis, AR was associated with favourable prognosis of BC irrespective of ER expression [15] .
Although AR is the main biological driver and therapeutic target in prostate cancer patients, its therapeutic targeting has been found to pose an anti-proliferative action in BC patients [19] . The use of androgens as hormonal therapy in BC has shown results that are generally comparable to Tamoxifen [20, 21] . For instance, fluoxymesterone, an androgen agonist, was studied in advanced BC patients decades ago with reported therapeutic responses of 14-53 % [22] [23] [24] . Taken together, this study aimed at assessing the prognostic and predictive significance of AR expression (protein and mRNA) in BC patients with emphasis on BC molecular subtypes.
Materials and methods
This study was based on the following:
I: A retrospective cohort comprising a well-characterised series of early invasive (TNM Stage I-III, excluding T3 and T4 tumours) primary operable BC patients presented to Nottingham City Hospital from 1987 to 1997. Tumours in these patients were 5 cm in diameter or less at time of presentation [25] . Patients were uniformly treated according to standard protocol; primary surgery, with either mastectomy or wide local excision, followed by radiotherapy. Before 1989, patients did not receive systemic adjuvant therapy. After 1989, the adjuvant treatment stratification of the patients in this cohort was based on prognostic and predictive factors including hormone receptor (ER) status, menopausal state and Nottingham prognostic index (NPI). Patients with good prognostic index (NPI \ 3.4) were considered low risk and did not receive adjuvant systemic therapy. Pre-menopausal women with an NPI [3.4 (high risk) received classical cyclophosphamide, methotrexate and 5-flurouracil (CMF) chemotherapy and patients with ER-positive tumours were offered hormone therapy (HT). Post-menopausal women with an NPI score [3.4 and ER-positivity were offered HT whilst ER-negative patients were offered classical CMF chemotherapy [26] .
Patients' clinical and pathological data including age, histological tumour type, primary tumour size, lymph node status, histological status, NPI [27] , and vascular invasion were available and prospectively maintained. This cohort has been well investigated using a wide range of biological markers of close relevance to BC biology and outcome. These markers include AR (previously stained in this cohort using anti-AR primary antibody, clone F39.4.1, Biogenex, UK, and the Streptavidin-Biotin ''ABC'' secondary detection method) [25] , ER, PR, HER2, cyokeratins (Ck), Cyclin B1, Ki67, and P53. For further insight into the relationship between ER and AR (i.e. ER-AR interaction), the ER-related proteins including FOXa1, GATA3, BEX1, PELP1, RERG, and TK1 were also used in this analysis. Survival data include Breast Cancer Specific Survival (BCSS), in months, from the date the primary surgical treatment to the time of death from breast cancer. Distant metastasis free interval (DMFI) was defined as the time, in months, taken from primary surgical treatment to the first distant recurrence. The duration of patients' follow-up in this study was 306 months and with 1136 patients had survival data at the end of follow-up time. Clinicopathological data of this series are presented in supplementary Table 1 . A subset of this cohort (n = 284) was included in the multicentre study-the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study, for which the human genome has been characterised. For this subset, mRNA was extracted from fresh frozen tumours and hybridised to Illumina HT-12 v3 platform (Bead Arrays) and the data were pre-processed and normalised as previously described [28] . The AR mRNA expression was investigated in this subset. Correlation co-efficient was This study adheres to REporting recommendations for tumour MARKer prognostic studies (REMARK) criteria [29] .
Immunohistochemistry (IHC)
Validating the antibody specificity Prior to IHC, the specificity of the anti-AR primary antibody (Sc-816, Santa Cruz Biotechnology, UK) was validated using Western blotting (WB). WB was performed on whole cell lysates of MCF-7 and MDA-MB 231 human BC cell lines (obtained from the American Type Culture Collection; Rockville, MD, USA) using 1:100 dilution of the primary antibody dilution, and 1:2000 of the HRP labelled secondary anti-rabbit antibody, as previously described [30] . This showed a single specific band at the predicted size (110 kDa) of AR protein, confirming the specificity of the antibody (Fig. 1a) .
Procedure of immunohistochemistry
IHC was applied to tissue microarrays (TMA) using Novolink TM Max Polymer Detection System from Leica Biosystems (Leica, Newcastle, UK). Heat-induced retrieval of antigen epitopes was performed in citrate buffer (pH 6) using microwave for 20 min. Anti-AR primary antibody (Sc-816, Santa Cruz Biotechnology, UK) was applied, diluted at 1:40, for 60-minutes incubation. For reaction visualisation, 3-3' Diam inobenzidine tetrahydrochloride (Novolink DAB substrate buffer plus) was used as a chromogen. Negative (primary antibody replaced by Phosphate-buffered saline (PBS) and positive controls (FFPE tissue section of a known AR-positive BC case) were included in the staining run. 
Assessment of IHC staining
Slides were scanned into high-resolution digital images (0.45 lm/pixel) using a NanoZoomer slide scanner (Hamamtsu Photonics, Welwyn Garden City, UK) and uploaded into web server where they could be accessed using a web-based interface (Distiller, Leica). TMA cores were scored at 920 magnification using a minimum of 24'' highresolution computer screen (1920 9 1080). The semiquantitative IHC scoring (H-score) method was used, which takes the intensity and percentage of stained invasive tumour tissue stained into account [31] . All cases were scored without prior knowledge of the patients' pathologic or outcome data. Although, cytoplasmic staining was observed in some TMA cores, only nuclear staining was considered in this study. Breast cancer molecular subtypes were defined based on their IHC expression profile into: (1) luminal/hormone receptor (HR)?; ER? and/or PR?, (2) HER2? (HER2? regardless of the expression of other markers), (3) Triplenegative basal-like; ER-, PR-, HER2-, and positive for CK5/6, and/or CK14 and/or EGFR and (4) triple-negative non-basal BC; all above markers negative), as previously described [32] .
II: External validation cohorts: For external validation of AR mRNA expression, bc-GenExMiner v3.0 (Breast Cancer Gene-Expression Miner v3.0) online dataset (http://bcgenex.centregauducheau.fr) was used. In this study, the ''prognostic module'', offering the possibility to evaluate the prognostic impact of candidate genes in breast cancer, was used [33] . Cox model, Kaplan-Meier and forest plots were generated.
Statistical analysis
The statistical analysis was performed using Statistical Package for Social Sciences SPSS version 21 for Windows (SPSS Inc., Chicago, IL, USA). A p value (two-tailed) of less than 0.05 was considered significant. Spearman correlation co-efficient was used to test for correlation between continuous variables. Cut-off values for the different biomarkers included in this study were chosen before statistical analysis. Standard cut-offs were used for established prognostic factors and were the same as for previously published patient series [32] . Determination of the optimal AR H-score cut-offs was obtained using X-tile bio-informatics software [34] . Analysis of categorical variables was performed using the appropriate statistical test. Kaplan-Meier plots were used to visualise the survival distribution of dichotomised AR, with differences in survival estimated using Log-rank tests. Multivariate Cox proportional hazards model was fitted to adjust for confounders and test statistical independence of AR in predicting BCSS and DMFS.
Results

I: AR IHC results
The number of BC cases informative on the TMA for AR expression in this study was 1141. 
Associations of AR IHC expression with clinicopathological features and other markers
Nuclear expression of AR showed positive association with patients' age (p \ 0.001) and pathological features of good prognosis including smaller tumour size (p = 0.001), lower histological grade, more tubule formation, less pleomorphism and low mitotic counts, lobular histological type and special tumour types of excellent prognosis, and low NPI score (p \ 0.001). Negative association was observed with tumours of medullary-like histology. Importantly, AR expression was negatively associated with mitosis in the whole series, irrespective of ER status. Within the whole series, AR was positively associated with luminal-enriched proteins FOXa1, GATA3, BEX1, PELP1, and RERG, while negative association was observed with the HER2? status (p = 0.003), P53 status, Ki67LI, and CD71 (p \ 0.001).
AR was associated with BC molecular intrinsic subtypes as defined by IHC surrogate markers [32] (p \ 0.001, and p = 0.034, for the whole series and ER? tumours, respectively; Table 2 Table 2 ).
Associations of AR with patients' outcome
High expression of AR was associated with longer BCSS [Log rank (LR) = 17.88, p \ 0.001; Fig. 2a] . In ER-positive tumours, higher AR levels were predictive of longer BCSS (LR = 14.58; p \ 0.001; Fig. 2b) . Cox proportional multivariate analysis showed that higher AR level of expression was an independent indicator of better outcome irrespective of tumour size, grade and nodal stage [p = 0.033, hazard ratio (HR) = 0.80 95 % CI = 0.64-0.98; Table 3 ). Multivariate analysis showed that AR is an independent prognostic marker (p = 0.007, HR = 0.71 95 % CI = 0.56-0.91; Table 3 ). However, inclusion of Ki67LI into the cox proportional hazard model rendered AR expression insignificant [p = 0.255, 0.091, for the whole series and luminal type, respectively).
Regarding distant metastasis, there was an association between low levels of AR expression and probability of development of DM (LR = 23.32; p \ 0.001), Fig. 2c . This relationship was maintained using a Cox regression model which showed that AR was an independent predictor of longer DMFI (HR = 0.80; p = 0.034; 95 % CI = 0.65-0.98). A similar association was also observed in the luminal subgroup (Fig. 2d) . Inclusion of Ki67LI into the cox proportional hazard model rendered AR expression statistically insignificant (p = 0.690, 0.550, for the whole series and luminal type, respectively).
The favourable prognostic significance of AR expression was evident in ER-positive patients regardless of their hormonal therapy status. Patients who received, as well as those who did not receive hormonal therapy (HT), showed significant survival advantage in the AR-positive group, Fig. 3a, b respectively. Considering adjuvant chemotherapy, the prognostic advantage of positive AR expression was maintained in patients with ER-positive disease who either received or did not receive adjuvant chemotherapy (LR = 4.62, p = 0.032, LR = 8.06, p = 0.005, respectively, Fig. 3c, d ). Using X-tile, AR was able to stratify BC patients into three prognostic groups; those with AR expression level less than 200 H-score had shorter 15 When the analysis was restricted to the TNBC and HER2? phenotypes, nuclear AR expression was neither associated with BCSS nor with DMFI even when using different cut-off point for dichotomisation of AR expression (data not shown).
II: AR mRNA expression
AR mRNA expression was assessed in a subset of cases that were included in the METABRIC study [35] (n = 284 cases). This showed a significant positive correlation between AR protein IHC expression and AR mRNA expression (r = 0.424, p \ 0.001). AR mRNA showed significantly higher expression in low-grade tumours (Oneway ANOVA (F) = 5.046, p = 0.007) with low proliferative activity as assessed by mitotic scores (F = 8.056, p \ 0.001) and Ki67LI (r = 0.403, p \ 0.001).
Significant differences were observed between BC molecular subtypes (F = 29.361, p \ 0.001), with highest expression observed in the luminal/ER? subtype. Within the luminal/ER? tumours using the median cut-off, high AR mRNA expression showed longer BCSS as compared to low expression, at 10 and 15 of follow-up with a trend towards significant association at 20 years of follow-up (data not shown).
B: External validation cohorts
Using bc-GenExMiner v3.1 (Breast Cancer Gene-Expression Miner v3.1) online dataset as external validation cohorts, the prognostic impact of AR mRNA expression was investigated. As shown in the Forest plot (Supplementary Fig. 1 ), 25 datasets were investigated. In 5/25 studies, high AR mRNA expression was significantly associated with improved survival, in one dataset (n = 155 Bold indicates p values that are statistically significant patients) it was significantly associated with shorter survival, while the rest of data sets did not show significant association with outcome (Supplementary Table 2 ). When data of all datasets were pooled together (n = 4078), high AR mRNA expression was significantly associated with better metastatic recurrence (MR) free survival (p \ 0.001, HR = 0.78, 95 % CI 0.69-0.88; Supplementary Fig. 1 ). This association was maintained in the ER-positive datasets (p = 0.0017, HR = 0.78, 95 % CI 0.67-0.91). However, associations of AR with improved outcome deemed statistically insignificant when the analysis was adjusted for proliferation both in the whole and ER-positive datasets (n = 2528 patients, p = 0.8824 and n = 1907, p = 0.6654, respectively).
Discussion
Despite being an important member of the steroid receptor superfamily, its frequent expression in BC and its relation to ER, the biological and clinical significance of AR remains under investigation. Although multiple authorities have reported a good prognostic impact of AR expression in BC [36, 37] , others have described that patients with AR over-expressing ER-negative BC have shorter survival [38] . Molecular apocrine class, which is characterised by AR expression and pathway activation typically lacks ER expression and is associated with poor prognosis. Moreover, the magnitude of AR expression impact on outcome has been variably reported in different BC molecular subtypes and whether it is dependent on ER or proliferation remains to be defined. In addition, the correlation between AR mRNA and AR protein expression and the clinical significance of each remains to be characterised. In this study, there was high prevalence of AR expression, more than ER and PgR expression, with those cases showing complete absence of AR forming a minority of cases. This goes in line with previous reports [39, 40] . Interestingly, in studies that have utilised smaller number of patients, it has been shown that AR is frequently expressed in some special types of invasive BC more than others such as apocrine and invasive lobular carcinoma [41] [42] [43] [44] . Our study supports these findings and demonstrates that AR expression is significantly higher in invasive lobular carcinoma as well as other special histologic types of excellent prognosis. These associations were significant in the whole series, ER?, and ER-subgroups.
Consistent with previous studies [18, 45, 46] , our results showed an association between AR expression features of good prognosis including older patient age, small tumour size, lower tumour grade with lower proliferative activity as well as HR positivity. The interaction between AR and ER in down-regulation cancer cell proliferation has led some authorities to speculate that combined selective oestrogen/androgen hormone modulators may be an alternative promising modality to the current modalities in HR positive BC [47, 48] . In this study, luminal BC showed the highest expression of AR compared to HER-positive and TN tumours. Moreover, AR was associated with markers known to be regulated via ER and more expressed in luminal BC such as GATA3, FOXa1, CARM1, RERG, PELP1, AGTR1, CD71, and BEX1. From these results, it appears that AR prognostic value of expression varies significantly depending on the ER status of the tumour. In line with notion, it has been suggested that the dependency of AR on ER status is related to the competitive interaction between AR and ER [5] , where in the presence of the latter, AR interacts with oestrogen response elements on ER, blocking downstream oestrogen target genes, leading to inhibition of ER-stimulated tumour proliferation. Contrasting this, when ER is lacking/absent, AR interacts with AR elements and promotes tumour cell growth [49] . In line with this is the report of Elebro and co-authors who reported on the interaction of AR and ER in determining the impact of AR expression [50] .
Regarding the association with patients' outcome, AR overexpression was shown to be significantly associated with improved outcome in the whole series and in ERpositive BC. These associations were independent of other well-established prognostic variables including tumour size, grade and nodal stage. However, this prognostic advantage of AR expression was lost upon inclusion of proliferative fraction, as assessed by Ki67LI, into the multivariable model, indicating dependency of AR on tumour proliferation.
In this study, AR mRNA expression showed a positive correlation with AR protein expression. Consistent with AR protein expression, higher AR mRNA expression was observed in low-grade tumours, and was differentially expressed in BC molecular subtypes, with highest was observed in the luminal/ER-positive subtype conferring better outcome as compared to low expression both as early as late during follow-up period (at 10 and 15 years). Furthermore, 25 online datasets were investigated for AR mRNA expression as external validation cohorts. Significantly longer distant recurrence free survival was observed with high AR mRNA expression both in unselected (n = 4078) and ER-positive datasets. Once again, these associations deemed statistically insignificant upon adjustment for proliferation in the whole datasets and in ER? datasets. Therefore, AR prognostic significance appears to be highest in ER? low proliferative tumours and results in line with AR IHC in our BC series.
It is noteworthy that the improved outcome of high AR IHC expression was maintained in patients who received adjuvant hormonal or chemotherapy, or did not receive adjuvant therapy. In both instances of adjuvant therapy, patients with AR positive tumours performed better than those with AR negative tumours. Therefore, adjunctive therapeutic manipulation of AR, with or without other therapies, could be useful in improving outcome, especially in chemotherapy-intolerant patients. Moreover, not only the status of AR as assessed by IHC which could stratify patients, but the level of AR expression was also useful in distinguishing three distinct prognostic groups in BC. Cases which expressed highest levels of AR survived the longest while those with tumours expressed lowest AR levels survived significantly shorter periods. This finding can have useful implications on treatment selection for specific AR expression subgroups of BC patients.
TNBC are regarded as a heterogeneous subtype of BC with chemotherapy as the mainstay of treatment for both early-stage and advanced invasive TNBC. In this study, 20 % of TNBC showed overexpression of AR at H score = 190 cut-off point. However, 85 % of cases of TNBC expressed AR showing 1 % or more of staining. Accordingly, AR expression was not only expressed in the ER?/luminal tumours but also in the TNBC. However, it was not significantly associated with patients' outcome in the TNBC neither in the basal phenotype tumours at cutoff point used for the whole series and the ER? subgroup nor with other cut-offs. Current studies are investigating novel therapeutic strategies in phase II and phase III clinical trials. The anti-androgens for AR-positive TNBC are amongst those molecularly targeted therapies currently being tested [51] . Although findings in our data did not show prognostic significance of AR in TNBC, this does not preclude the potential utility of AR molecular targeted therapies for TNBC tumours. It is worth mentioning that variable results of AR expression in literature, both in unselected and different intrinsic molecular subtypes, could be attributed to many reasons. These include the inherent heterogeneous nature of invasive BC, intratumoural heterogeneity of AR expression, using different antibody clones or secondary detection kits with variable sensitivity, or inter-observer variability in interpreting the IHC staining. In our study, the overall agreement between the used antibody in this study and a previously used clone [32] showed excellent agreement. Moreover, it produced the same associations with clinicopathological, biomarker and patients' outcome (data not shown).
The use of such therapy stands as a potential avenue especially in case of treatment failure/resistance with the currently used chemotherapeutic regimens [52, 53] . Meanwhile, several issues that surround the expression of AR in BC should be addressed, such as its relationship with the HER2-pathway, and most importantly if the receptor expressed in BC is different from ARs expressed in other tissues of the body [54, 55] . Should similarities be present, they will be critical to minimise any potential side effects associated with any future AR-targeted therapy.
In conclusion, AR is abundantly expressed in invasive BC with significant association with favourable prognostic parameters both at protein and transcriptomic levels. It is an independent prognostic factor and can further stratify the patient into distinct prognostic subgroups significantly different in outcome. There is interaction between AR and ER and proliferation which may explain the differential prognostic effect of AR in BC. Understanding these biological interactions may help in utilising AR as a molecular therapeutic target in invasive BC.
